Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer.
Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, Dragoni I, Heinzmann K, Potter S, Salisbury BM, Chénard-Poirier M, Greystoke A, Howell EC, Innes WA, Morris K, Plummer C, Rata M, Petrides G, Keun HC, Banerji U, Plummer R. Halford S, et al. Among authors: banerji u. Clin Cancer Res. 2023 Apr 14;29(8):1429-1439. doi: 10.1158/1078-0432.CCR-22-2263. Clin Cancer Res. 2023. PMID: 36652553 Free PMC article. Clinical Trial.
Hsp90 inhibitors in the clinic.
Pacey S, Banerji U, Judson I, Workman P. Pacey S, et al. Among authors: banerji u. Handb Exp Pharmacol. 2006;(172):331-58. doi: 10.1007/3-540-29717-0_14. Handb Exp Pharmacol. 2006. PMID: 16610366 Review.
Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
Geh JI, Glynne-Jones R, Kwok QS, Banerji U, Livingstone JI, Townsend ER, Harrison RA, Mitchell IC. Geh JI, et al. Among authors: banerji u. Clin Oncol (R Coll Radiol). 2000;12(3):182-7. doi: 10.1053/clon.2000.9147. Clin Oncol (R Coll Radiol). 2000. PMID: 10942336
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM. Banerji U, et al. Clin Cancer Res. 2010 Mar 1;16(5):1613-23. doi: 10.1158/1078-0432.CCR-09-2483. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179232 Free article. Clinical Trial.
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I. Pacey S, et al. Among authors: banerji u. Clin Cancer Res. 2011 Mar 15;17(6):1561-70. doi: 10.1158/1078-0432.CCR-10-1927. Epub 2011 Jan 28. Clin Cancer Res. 2011. PMID: 21278242 Free PMC article. Clinical Trial.
142 results